We sought to investigate the direct effects of glucagon receptor activation in a clinically relevant model of obesity-associated hyperglycaemia, using a peptide agonist which was over ten times more potent at the glucagon than the GLP-1 receptor. Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.